WATERTOWN, Mass.--(BUSINESS WIRE)--June 14, 2006--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC - News), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today presented data demonstrating lack of rapid emergence of resistance to bevirimat in single and multiple dose monotherapy studies in HIV infected patients. The study, presented at the XV International HIV Drug Resistance Workshop in Sitges, Spain, was the result of a collaboration between Panacos and Dr. Eric Freed's group in the HIV Drug Resistance Program at the National Cancer Institute, Frederick, MD, USA.
